Rodrigo Oliveira Moreira

Rodrigo Oliveira Moreira

Auto-generated profile, based on publicly available information

Rodrigo Oliveira Moreira

Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione (IEDE), Rio de Janeiro, Brazil

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2008 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
RMRodrigo O. Moreira
Rodrigo O. Moreira
RMRustan B. M. Moreira
Rustan B. M. Moreira
NMNikolas A. M. Machado
Nikolas A. M. Machado
TGTatiana B. Gonçalves
Tatiana B. Gonçalves
WCWalmir F. Coutinho
Walmir F. Coutinho

7 October 2011 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
MPMarcelo Papelbaum
Marcelo Papelbaum
RMRodrigo O Moreira
Rodrigo O Moreira
WCWalmir Coutinho
Walmir Coutinho
RKRosane Kupfer
Rosane Kupfer
LZLeão Zagury
Leão Zagury
JAJose Appolinario
Jose Appolinario
Comorbid depression in diabetes has been suggested as one of the possible causes of an inadequate glycemic control. The purpose of this study was to investigate the association between major depression and the glycemic control of type 2 diabetes mellitus (T2DM). Seventy T2DM patients were evaluated. They underwent a psychiatric examination using the following instruments: Structured Clinical Interview for DSM-IV and Beck Depression Inventory. The diabetes status was assessed in the short-term (glycemia, glycated hemoglobin) clinical control. The presence of current depression was observed in 18.6% (13/70). In addition, type 2 diabetes patients who displayed depression evidenced higher levels of glycated hemoglobin (8.6 ± 2.0 vs. 7.5 ± 1.8; p = 0.05) when compared to those who did not exhibit a mood disorder. In our sample, the presence of depression seems to impact on the short-term control of T2DM. The authors discuss the clinical utility of these findings in the usual treatment of diabetes.

1 December 2005 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
RMRodrigo O. Moreira
Rodrigo O. Moreira
ACAlessandra P. Castro
Alessandra P. Castro
MPMarcelo Papelbaum
Marcelo Papelbaum
JAJosé C. Appolinário
José C. Appolinário
VEVivian C.M. Ellinger
Vivian C.M. Ellinger
LZLeão Zagury
Leão Zagury
O objetivo deste trabalho é traduzir para o português e avaliar a confiabilidade de uma escala para diagnóstico da polineuropatia distal diabética (PNDD). O processo de tradução e adaptação para o português das versões simplificadas do Escore de Sintomas Neuropáticos (ESN) e Escore de Comprometimento Neuropático (ECN) foi realizado conforme as orientações internacionais padronizadas. As escalas foram aplicadas por dois avaliadores em 57 pacientes diabéticos selecionados seqüencialmente. Foi utilizada a correlação de Spearman para avaliação da concordância inter-avaliador e o alfa de Cronbach para avaliação da consistência interna do ESN. Tanto a aplicação do ECN como do ESN apresentou uma boa concordância entre os avaliadores (r= 0,77, p< 0,0001 e r= 0,76, p< 0,0001, respectivamente). O ESN apresentou boa consistência interna (alfa= 0,74). O diagnóstico de PNDD, realizado através da combinação dos escores, também apresentou boa concordância (r= 0,63, p< 0,0001). As versões em português do ECN e do ESN se mostraram adequadas para o diagnóstico da PNDD na população avaliada.

7 December 2023 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
CVCynthia Melissa Valerio
Cynthia Melissa Valerio
CVCristiane Villela-Nogueira
Cristiane Villela-Nogueira
CCCintia Cercato
Cintia Cercato
Fernando GerchmanFernando Gerchman
Fernando Gerchman
COClaudia Oliveira
Claudia Oliveira
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societies was organized to develop an evidence-based guideline on the screening, diagnosis, treatment, and follow-up of MASLD. Material and methods: A MEDLINE search was performed to identify randomized clinical trials, meta-analyses, cohort studies, observational studies, and other relevant studies on [...] ABSTRACT Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as Nonalcoholic fatty liver disease (NAFLD), is one of the most common hepatic diseases in individuals with overweight or obesity. In this context, a panel of experts from three medical societies was organized to develop an evidence-based guideline on the screening, diagnosis, treatment, and follow-up of MASLD. Material and methods: A MEDLINE search was performed to identify randomized clinical trials, meta-analyses, cohort studies, observational studies, and other relevant studies on

23 December 2013 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
EGErika P Guedes
Erika P Guedes
EMEduardo Madeira
Eduardo Madeira
MMMafort Mafort
Mafort Mafort
MMMiguel Madeira
Miguel Madeira
RMRodrigo O Moreira
Rodrigo O Moreira
MFMaria Lúcia Fleiuss De Farias
Maria Lúcia Fleiuss De Farias
Several studies point to a correlation between obesity and the severity of depressive and anxiety symptoms in children and adults, but there are still some controversial points about this association. The aim of this study is to investigate the relationship between body composition and the severity of anxiety/depressive symptoms in overweight and obese individuals with Metabolic Syndrome (MS).

3 April 2018 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
RMRodrigo Oliveira Moreira
Rodrigo Oliveira Moreira
RCRoberta Cobas
Roberta Cobas
RCRaquel C. Lopes Assis Coelho
Raquel C. Lopes Assis Coelho
Glycemic control has been considered a major therapeutic goal within the scope of diabetes management, as supported by robust observational and experimental evidence. However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic control, but also cardiovascular safety. Basal insulin is a highly effective treatment in reducing fasting blood glucose, but it is associated with considerable risk of hypoglycemia and weight gain. Glucagon like peptide 1 receptor agonists (GLP-1 RAs) are also effective in terms of glycemic control and associated with weight loss and low risk of hypoglycemia. The potential benefits of combining GLP-1RAs with basal insulin are contemplated in the current position statement of several different position statement and guidelines. This article reviews the efficacy and safety of different strategies to initiate and intensify basal insulin, with focus on new fixed ratio combinations of basal insulin with GLP-1 RAs available for use in a single injection pen (insulin degludec/liraglutide and insulin glargine/lixisenatide).